Neuroprotection Peptides

A synthetic peptide analog of tuftsin studied for anxiolytic and nootropic properties.

A synthetic peptide derived from ACTH, studied for cognitive enhancement and neuroprotective effects.

A mitochondria-targeted peptide FDA-approved as FORZINITY (elamipretide) for Barth syndrome in September 2025 — the first FDA-approved mitochondrial-targeted therapeutic.

A hexapeptide analog studied for cognitive enhancement via hepatocyte growth factor pathway activation.

A porcine brain-derived peptide mixture approved in some countries for stroke recovery and neurodegenerative conditions.

A GLP-1 receptor agonist FDA-approved for type 2 diabetes and chronic weight management.

A coenzyme essential for cellular energy production, studied for anti-aging and metabolic support.

A short bioregulatory peptide studied for neuroprotective effects and cognitive support in aging.

A neuropeptide with broad neuroimmune functions, studied for inflammatory conditions and nerve repair.

A brain-targeting tetrapeptide studied for neuroprotection and targeted drug delivery to injured brain and spinal cord tissue.

An 11-amino-acid CNTF-derived peptide studied for its ability to upregulate BDNF expression and promote neurogenesis in cognitive decline models.